Blinatumomab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Blinatumomab
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Blinatumomab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

59 Drugs in Development

59 Drugs in Development

FINISHED DOSAGE FORMULATIONS

15 FDF Dossiers, 1 FDA Orange Book, 2 Europe, 1 Canada, 10 Australia, 1 South Africa

15 FDF Dossiers
1 FDA Orange Book
2 Europe
1 Canada
10 Australia
1 South Africa

DIGITAL CONTENT

24 News #PharmaBuzz

24 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 18 Annual Reports

1 US Medicaid Prescriptions
1 Regulatory FDF Prices
18 Annual Reports

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Amgen Canada Inc.

filter Patent Reset all filters

6 All

01 12326389

02 12544532

03 12633594

04 12742242

05 12742249

06 12774919

filter Product Reset all filters

6 All

01 6BLINATUMOMAB

filter Dosage Reset all filters

6 All

01 6POWDER FOR SOLUTION

filter Exp Date Reset all filters

6 All

01 12019-04-21

02 12024-11-26

03 12026-11-29

04 22029-11-06

05 12030-10-27

Product Main Page

01

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-04-21

Date Granted : 2007-01-23

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2326389

Filing Date : 1999-04-21

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2019-04-21

Date Granted : 2007-01-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-11-26

Date Granted : 2015-06-16

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2544532

Filing Date : 2004-11-26

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-11-26

Date Granted : 2015-06-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

Country

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-06

Date Granted : 2020-07-21

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2742249

Filing Date : 2009-11-06

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2029-11-06

Date Granted : 2020-07-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

Country

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-11-29

Date Granted : 2021-10-26

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2633594

Filing Date : 2006-11-29

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2026-11-29

Date Granted : 2021-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

Country

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-27

Date Granted : 2022-03-08

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2774919

Filing Date : 2010-10-27

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2030-10-27

Date Granted : 2022-03-08

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Amgen Canada Inc.

BLINATUMOMAB

iPHEX India

Not Confirmed

Amgen Canada Inc.

Country

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-06

Date Granted : 2023-01-10

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2742242

Filing Date : 2009-11-06

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2029-11-06

Date Granted : 2023-01-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!